Free Newsletter
Pharma R&D company scrutinizes software assets
UK-based FAST Ltd. finds in recent research that 60 percent of companies are under-licensed and 40 percent are over-licensed with their software. It cites Eisai, which manages the functions of marketing and sales, finance, medical information, market research and business operations for the pharmaceutical R&D operations of Eisai Europe and Eisai U.K., as one company that has benefited from implementing a software asset management program. Announcement
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: